Oslo University Hospital announces the startup of a multicentre randomized phase 2 trial of ILB® in ALS, commencing early 2026. The study will compare ILB® to Riluzole, the current standard of care, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results